ATE199261T1 - Hybride immunglobuline - Google Patents

Hybride immunglobuline

Info

Publication number
ATE199261T1
ATE199261T1 AT91901202T AT91901202T ATE199261T1 AT E199261 T1 ATE199261 T1 AT E199261T1 AT 91901202 T AT91901202 T AT 91901202T AT 91901202 T AT91901202 T AT 91901202T AT E199261 T1 ATE199261 T1 AT E199261T1
Authority
AT
Austria
Prior art keywords
immunolobulins
hybrid
useful
methods
peptides
Prior art date
Application number
AT91901202T
Other languages
English (en)
Inventor
Daniel J Capon
Laurence A Lasky
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23749509&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE199261(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE199261T1 publication Critical patent/ATE199261T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT91901202T 1989-11-22 1990-11-21 Hybride immunglobuline ATE199261T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/440,625 US5116964A (en) 1989-02-23 1989-11-22 Hybrid immunoglobulins
PCT/US1990/006849 WO1991008298A2 (en) 1989-11-22 1990-11-21 Fusion proteins consisting of a ligand binding protein and a stable plasma protein

Publications (1)

Publication Number Publication Date
ATE199261T1 true ATE199261T1 (de) 2001-03-15

Family

ID=23749509

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99123412T ATE396735T1 (de) 1989-11-22 1990-11-21 Hybride immunglobuline zur verwendung in therapeutischen verfahren
AT91901202T ATE199261T1 (de) 1989-11-22 1990-11-21 Hybride immunglobuline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99123412T ATE396735T1 (de) 1989-11-22 1990-11-21 Hybride immunglobuline zur verwendung in therapeutischen verfahren

Country Status (12)

Country Link
US (1) US5116964A (de)
EP (3) EP1970386A2 (de)
JP (2) JPH05503009A (de)
AT (2) ATE396735T1 (de)
CA (1) CA2072642C (de)
DE (3) DE69033705T3 (de)
DK (2) DK0526452T4 (de)
ES (2) ES2155819T5 (de)
GR (1) GR3035856T3 (de)
LU (1) LU91498I2 (de)
NL (1) NL300372I1 (de)
WO (1) WO1991008298A2 (de)

Families Citing this family (640)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
US6018026A (en) 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6685941B1 (en) 1988-11-23 2004-02-03 The Regents Of The University Of Michigan Methods of treating autoimmune disease via CTLA-4Ig
US6406697B1 (en) 1989-02-23 2002-06-18 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5242687A (en) * 1989-03-15 1993-09-07 Tkb Associates Limited Partnership Method of reducing cellular immune response involving T-cells using CD8-bearing antigen presenting cells
US7264944B1 (en) 1989-04-21 2007-09-04 Amgen Inc. TNF receptors, TNF binding proteins and DNAs coding for them
ATE289350T1 (de) 1989-04-21 2005-03-15 Amgen Inc Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US6267964B1 (en) * 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
US5395760A (en) * 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5945397A (en) * 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
NZ235148A (en) 1989-09-05 1991-12-23 Immunex Corp Tumour necrosis factor receptor protein and dna sequences
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
US5216132A (en) * 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
DE4037837A1 (de) * 1990-11-28 1992-06-04 Behringwerke Ag Zellfreie rezeptorbindungsteste, ihre herstellung und verwendung
EP1340769B1 (de) 1991-02-08 2005-02-09 Progenics Pharmaceuticals, Inc. CD4-gamma2- und CD4-IgG2-Chimären
US7070991B2 (en) * 1991-02-08 2006-07-04 Progenics Pharmaceuticals, Inc. Cells expressing a CD4-IgG2 chimeric heterotetramer
MX9203138A (es) * 1991-03-12 1992-09-01 Biogen Inc Dominio de enlace cd2-de antigeno 3 (lfa-3) asociado con funcion linfositos.
AU660981B2 (en) * 1991-03-12 1995-07-13 Astellas Us Llc CD2-binding domain of lymphocyte function associated antigen 3
US20030206899A1 (en) * 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) * 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US5318890A (en) * 1991-05-06 1994-06-07 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
US5851795A (en) * 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US5844095A (en) * 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
EP0533006A1 (de) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimäre Interleukin 5-Rezeptor/Immunoglobulin-Polypeptide
US6764681B2 (en) * 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US6399368B1 (en) 1992-01-17 2002-06-04 Board Of Regents, The University Of Texas System Secretion of T cell receptor fragments from recombinant Escherichia coli cells
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
AU671116B2 (en) * 1992-03-30 1996-08-15 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
WO1993022332A2 (en) * 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
WO1994005314A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of leukocyte adhesion
JPH07504203A (ja) * 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるｔｎｆ−依存性炎症の治療方法
DE69310525T2 (de) * 1992-09-16 1997-10-02 Genentech Inc Schutz gegen leberschäden mit hgf
WO1994006469A1 (en) * 1992-09-18 1994-03-31 La Jolla Institute For Allergy And Immunology Hiv fusion polypeptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
US5474766A (en) * 1992-12-18 1995-12-12 Washington University Methods and compositions for inhibition of hepatic clearance of tissue-type plasminogen activator
NZ261991A (en) * 1993-01-25 1998-04-27 Dana Farber Cancer Inst Inc Chimeric l and p selectin made by exchange of domains, uses thereof
US7534867B1 (en) 1993-05-19 2009-05-19 Schering Corporation Purified mammalian Flt3 ligands; agonists; antagonists
US6824779B1 (en) 1993-07-26 2004-11-30 Dana-Farber Cancer Institute, Inc. Methods for inhibiting the interaction of B7-2 with its natural ligand
US5861310A (en) * 1993-11-03 1999-01-19 Dana-Farber Cancer Institute Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6723705B1 (en) 1993-08-19 2004-04-20 Gentics Institute, Inc. Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6084067A (en) * 1993-07-26 2000-07-04 Dana-Farber Cancer Institute CTLA4/CD28 ligands and uses therefor
US20050129670A1 (en) * 1993-07-26 2005-06-16 Genetics Institute, Llc. Tumor cells modified to express B7-2 with increased immunogenicity and uses therefor
US6130316A (en) * 1993-07-26 2000-10-10 Dana Farber Cancer Institute Fusion proteins of novel CTLA4/CD28 ligands and uses therefore
SE9302855D0 (sv) * 1993-09-06 1993-09-06 Martin Lindberg Method and means for producing plasmaproteinase inhibitor binding proteins
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
JPH09509054A (ja) * 1994-02-01 1997-09-16 アメリカ合衆国 抗体部分および非抗体部分を含む融合タンパク質
US7294331B2 (en) * 1994-03-07 2007-11-13 Immunex Corporation Methods of using flt3-ligand in hematopoietic cell transplantation
WO1995024217A1 (en) * 1994-03-08 1995-09-14 Dana-Farber Cancer Institute Methods for modulating t cell unresponsiveness
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
IL113484A0 (en) * 1994-04-28 1995-07-31 Immunex Corp Viral proteins pharmaceutical compositions containing them their preparation and use
WO1995030750A2 (fr) 1994-05-06 1995-11-16 Institut Gustave Roussy Fractions polypeptidiques solubles de la proteine lag-3; procede de production; composition therapeutique; anticorps anti-idiotype
US6124448A (en) * 1994-08-17 2000-09-26 The Rockfeller University Nucleic acid primers and probes for the mammalian OB gene
US6350730B1 (en) 1994-08-17 2002-02-26 The Rockefeller University OB polypeptides and modified forms as modulators of body weight
US6471956B1 (en) 1994-08-17 2002-10-29 The Rockefeller University Ob polypeptides, modified forms and compositions thereto
US6001968A (en) 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6048837A (en) * 1994-08-17 2000-04-11 The Rockefeller University OB polypeptides as modulators of body weight
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814464A (en) * 1994-10-07 1998-09-29 Regeneron Pharma Nucleic acids encoding TIE-2 ligand-2
EP0793504B1 (de) * 1994-12-12 2005-06-08 Beth Israel Deaconess Medical Center, Inc. Chimäre zytokine und ihre verwendung
US6410008B1 (en) * 1994-12-12 2002-06-25 Beth Israel Hospital Association Chimeric IL-10 proteins and uses thereof
US6808709B1 (en) * 1994-12-30 2004-10-26 The Regents Of The University Of California Immunoglobulins containing protection proteins and their use
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6485726B1 (en) * 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6455685B1 (en) 1995-03-03 2002-09-24 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US20030069196A1 (en) * 1995-03-03 2003-04-10 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6066322A (en) 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
IL117645A (en) * 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US20060193862A1 (en) * 1995-03-30 2006-08-31 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US20020034517A1 (en) * 1995-10-04 2002-03-21 Kenneth Brasel Dendritic cell stimulatory factor
US7361330B2 (en) * 1995-10-04 2008-04-22 Immunex Corporation Methods of using flt3-ligand in the treatment of fibrosarcoma
US7150992B1 (en) 1995-10-04 2006-12-19 Innunex Corporation Methods of preparing dendritic cells with flt3-ligand and antigen
US6936439B2 (en) * 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
US20030040467A1 (en) * 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US20030026779A1 (en) * 1999-10-15 2003-02-06 Liming Yu Treatment of tumors and viral infections with a hybrid conjugate of interferon and an immunoglobulin Fc
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
DE69734443T2 (de) 1996-01-08 2006-07-13 Genentech, Inc., South San Francisco Ob-rezeptor und liganden
US6750334B1 (en) 1996-02-02 2004-06-15 Repligen Corporation CTLA4-immunoglobulin fusion proteins having modified effector functions and uses therefor
US5917026A (en) * 1996-02-05 1999-06-29 Loewenadler; Bjoern Fusion proteins of immunopotentiating activity
DE69739656D1 (de) 1996-02-09 2009-12-31 Amgen Inc 1 inhibitor und hyaluronan als polymer mit verzögerter wirkstofffreigabe
NZ331539A (en) * 1996-02-20 2000-01-28 Applied Research Systems Hybrid proteins from two coexpressed receptors to form a heterodimer
US6194177B1 (en) * 1996-02-20 2001-02-27 Applied Research Systems Ars Holding N.V. DNA encoding a hybrid heterodimeric protein
GB9604518D0 (en) * 1996-03-02 1996-05-01 Smithkline Beecham Plc Novel compounds
US6015884A (en) 1996-03-28 2000-01-18 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US7026116B1 (en) * 1996-04-04 2006-04-11 Bio-Rad Laboratories, Inc. Polymorphisms in the region of the human hemochromatosis gene
US6140305A (en) * 1996-04-04 2000-10-31 Bio-Rad Laboratories, Inc. Hereditary hemochromatosis gene products
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
US6060054A (en) * 1996-04-10 2000-05-09 National Jewish Medical And Research Center Product for T lymphocyte immunosuppression
US6117977A (en) * 1996-04-24 2000-09-12 Genentech, Inc. Type C lectins
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
US6451308B1 (en) 1996-04-26 2002-09-17 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
DE69733773T2 (de) * 1996-05-02 2006-04-20 Mochida Pharmaceutical Co. Ltd. Fas ANTIGEN-DERIVATE
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6849399B1 (en) 1996-05-23 2005-02-01 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron misregulation diseases
TW555765B (en) 1996-07-09 2003-10-01 Amgen Inc Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
EP0912734B1 (de) 1996-07-12 2010-11-03 Genentech, Inc. Chimärische heteromultimerische adhesine
WO1998002541A1 (en) * 1996-07-12 1998-01-22 Genentech, Inc. Gamma-heregulin
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
ATE247974T1 (de) 1996-12-06 2003-09-15 Amgen Inc Kombinationtherapie mit einem tnf-bindendem protein zür behandlung von durch tnf verursachten erkrangungen
ES2615357T3 (es) 1996-12-06 2017-06-06 Amgen Inc. Terapia de combinación usando un inhibidor de IL-1 para tratar enfermedades mediadas por IL-1
CA2279547A1 (en) * 1997-01-31 1998-08-06 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
US7435793B2 (en) * 1998-05-15 2008-10-14 Genentech, Inc. Peptides that induce chondrocyte redifferentiation
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE69837085T3 (de) 1997-04-16 2012-01-12 Millennium Pharmaceuticals, Inc. Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
US6190909B1 (en) * 1997-04-17 2001-02-20 Millennium Pharmaceuticals, Inc. TH2-specific gene
JP2002514079A (ja) * 1997-05-01 2002-05-14 アムジエン・インコーポレーテツド キメラｏｐｇポリペプチド
US20020062010A1 (en) * 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) * 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
DK0979281T3 (da) * 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20030207346A1 (en) * 1997-05-02 2003-11-06 William R. Arathoon Method for making multispecific antibodies having heteromultimeric and common components
AU745403B2 (en) 1997-06-13 2002-03-21 Bio-Rad Laboratories, Inc. Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
US6930170B2 (en) * 1997-06-16 2005-08-16 Genentech, Inc. PRO1184 polypeptides
US20040191256A1 (en) * 1997-06-24 2004-09-30 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
KR100220645B1 (ko) * 1997-07-04 1999-09-15 구광시 벤젠유도체의 제조방법
US6165476A (en) * 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US6242570B1 (en) 1997-07-10 2001-06-05 Beth Israel Deaconess Medical Center Production and use of recombinant protein multimers with increased biological activity
US6187564B1 (en) 1997-07-10 2001-02-13 Beth Israel Deaconess Medical Center DNA encoding erythropoietin multimers having modified 5′ and 3′ sequences and its use to prepare EPO therapeutics
US20030032103A1 (en) * 1997-09-18 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6391311B1 (en) * 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO1999020758A1 (en) * 1997-10-21 1999-04-29 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
US20040136986A1 (en) * 1997-10-31 2004-07-15 Genentech, Inc. Methods and compositions comprising glycoprotein glycoforms
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
ES2221717T3 (es) 1997-12-08 2005-01-01 Emd Lexigen Research Center Corp. Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general.
US6207413B1 (en) * 1998-01-22 2001-03-27 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding novel orphan cytokine receptors
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US7198789B2 (en) * 1998-03-17 2007-04-03 Genetics Institute, Llc Methods and compositions for modulating interleukin-21 receptor activity
US6057128A (en) 1998-03-17 2000-05-02 Genetics Institute, Inc. MU-1, member of the cytokine receptor family
US7189400B2 (en) * 1998-03-17 2007-03-13 Genetics Institute, Llc Methods of treatment with antagonists of MU-1
US7371836B2 (en) * 1998-03-27 2008-05-13 Genentech, Inc. PRO526 nucleic acids
US7723488B2 (en) * 1998-03-27 2010-05-25 Genentech, Inc. Monoclonal antibodies to secreted and transmembrane polypeptides
ES2267263T3 (es) * 1998-04-15 2007-03-01 Emd Lexigen Research Center Corp. Coadministracion de un inhibidor de la angiogenesis para reforzar la respuesta inmunologica por medio de la mediacion de una proteina de fusion de una citoquina con un anticuerpo.
JP3577586B2 (ja) * 1998-05-15 2004-10-13 ジェネンテック・インコーポレーテッド Ｉｌ−１７相同的ポリペプチドとその治療用途
US20020192751A1 (en) * 1998-05-15 2002-12-19 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999064461A2 (en) 1998-06-12 1999-12-16 Genentech, Inc. Monoclonal antibodies, cross-reactive antibodies and method for producing the same
CA2330527A1 (en) * 1998-06-15 1999-12-23 Genzyme Transgenics Corporation Erythropoietin analog-human serum albumin fusion
US20050181482A1 (en) * 2004-02-12 2005-08-18 Meade Harry M. Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US20070003545A9 (en) * 1999-06-02 2007-01-04 Eaton Dan L Interleukin-8 homologous polypeptides and therapeutic uses thereof
US20030065154A1 (en) * 2000-03-30 2003-04-03 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
US20020099197A1 (en) * 1998-07-21 2002-07-25 Rory A.J. Curtis Novel potassium channel molecules and uses therefor
IL141486A0 (en) * 1998-08-31 2002-03-10 Biogen Inc Pharmaceutical compositions containing a cd2 binding agent
HU229888B1 (en) 1998-10-16 2014-11-28 Biogen Idec Ma Inc Cambridge Polymer conjugates of interferon betha-1a and uses
EE05111B1 (et) * 1998-10-16 2008-12-15 Biogen, Incorporated Interferoon-beetaga sulandatud valgud ja nende kasutamine
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
DK2319928T3 (da) 1998-10-23 2013-06-24 Kirin Amgen Inc Dimere trombopoietiske peptidomimetika, der binder til MPL-receptor og har trombopoietisk aktivitet
WO2000027885A1 (en) * 1998-11-05 2000-05-18 Kyowa Hakko Kogyo Co., Ltd. Novel chimeric polypeptide
WO2000028035A1 (en) * 1998-11-10 2000-05-18 Human Genome Sciences Inc. CHEMOKINE β-7
US7294482B2 (en) * 1998-11-19 2007-11-13 Millennium Pharmaceuticals, Inc. EGF-like nucleic acids
US7235642B1 (en) * 1999-01-12 2007-06-26 Genentech, Inc. Anti-PRO 1313 antibodies
US6656728B1 (en) 1999-02-08 2003-12-02 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
EP1854480A3 (de) 1999-03-19 2009-04-01 Genentech, Inc. Behandlung von LFA-1-assoziierten Krankheiten durch gesteigerte Dosen von LFA-1-Antagonist
US7011833B1 (en) * 1999-05-06 2006-03-14 Genetics Institute, Inc. Enhancing immune responses with B7-1 or B7-2 in the absence of a crosslinking agent
US20050079577A1 (en) * 1999-05-14 2005-04-14 Ashkenazi Avi J. Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE60035871T2 (de) * 1999-05-19 2008-06-05 Merck Patent Gmbh Expression und export von interferon-alpha proteinen als fc fusionsproteine
AU782493B2 (en) * 1999-06-01 2005-08-04 Curis, Inc. Polymer conjugates of hedgehog proteins and uses
AU5309600A (en) * 1999-06-02 2000-12-18 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6924359B1 (en) * 1999-07-01 2005-08-02 Yale University Neovascular-targeted immunoconjugates
IL147269A0 (en) * 1999-07-02 2002-08-14 Genentech Inc FVIIa ANTAGONISTS
EP1189931B1 (de) 1999-07-02 2006-06-21 Genentech, Inc. An her2 bindende peptidverbindungen
JP2003506017A (ja) * 1999-07-12 2003-02-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング セリパンクリン
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
ATE279437T1 (de) * 1999-08-06 2004-10-15 Genentech Inc Peptidantagonisten des faktors viia
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
WO2001014557A1 (en) 1999-08-23 2001-03-01 Dana-Farber Cancer Institute, Inc. Pd-1, a receptor for b7-4, and uses therefor
US20030166858A1 (en) * 1999-09-16 2003-09-04 Samuel Davis TIE-2 ligands, methods of making and uses thereof
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
IL149202A0 (en) * 1999-11-05 2002-11-10 Biogen Inc Hedgehog fusion proteins and uses
CA2391080A1 (en) 1999-11-12 2001-05-25 Merck Patent Gesellschaft Mit Beschraenkter Haftung Erythropoietin forms with improved properties
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
US7122632B2 (en) * 1999-12-23 2006-10-17 Zymogenetics, Inc. Soluble Interleukin-20 receptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
US7307153B2 (en) * 1999-12-23 2007-12-11 Genentech, Inc. Antibodies that bind PRO9912
US20030153015A1 (en) * 2000-01-20 2003-08-14 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK1252192T3 (da) * 2000-02-11 2006-11-20 Merck Patent Gmbh Forbedring af antistofbaserede fusionsproteiners serumhalveringstid
CN1322897C (zh) * 2000-02-21 2007-06-27 应用研究系统Ars股份公司 Il－18抑制剂的应用
US7541184B2 (en) * 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US7572631B2 (en) * 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US20060073547A1 (en) * 2000-03-01 2006-04-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6984519B2 (en) 2000-03-01 2006-01-10 Genetech, Inc. Nucleic acids encoding peptides that induce chondrocyte redifferentiation
US20060002943A1 (en) * 2000-03-02 2006-01-05 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US7514239B2 (en) * 2000-03-28 2009-04-07 Amgen Inc. Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
CA2405800A1 (en) * 2000-04-10 2001-10-18 Merck Patent Gesellschaft Mit Beschraenkter Haftung Novel secreted protein
US20050100991A1 (en) * 2001-04-12 2005-05-12 Human Genome Sciences, Inc. Albumin fusion proteins
JP2003530838A (ja) * 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
US6946134B1 (en) 2000-04-12 2005-09-20 Human Genome Sciences, Inc. Albumin fusion proteins
EP1286692A4 (de) * 2000-04-25 2004-11-17 Idec Pharma Corp Intrathekale verabreichung von rituximab zur behandlung von lymphomen des zenralen nervensystems
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
US20060015969A1 (en) * 2000-04-28 2006-01-19 Planet Biotechnology, Inc. Novel immunoadhesins for treating and prventing toxicity and pathogen-mediated diseases
US7951378B2 (en) * 2000-04-28 2011-05-31 Planet Biotechnology Inc. Immunoadhesin comprising a chimeric ICAM-1 molecule produced in a plant
JP2003533187A (ja) * 2000-05-03 2003-11-11 アムジエン・インコーポレーテツド 治療薬としてのＦｃドメインを含む修飾ペプチド
US20020102232A1 (en) * 2000-05-11 2002-08-01 Chang Tse W. Compositions and methods for induction of active autoimmunity
BR0110779A (pt) * 2000-05-12 2005-01-11 Beth Israel Hospital Composições e métodos para adquirir supressão imunológica
EP1714661A3 (de) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Verfahren zur Diagnose und Behandlung von hämostatischen Störungen durch Modulation der P-Selectin Aktivität
US20040034193A1 (en) * 2001-06-13 2004-02-19 Samy Ashkar Biosynthetic oncolytic molecules and uses therefor
US20050048614A1 (en) * 2000-06-13 2005-03-03 Children's Medical Center Corporation Biosynthetic oncolytic molecules and uses therefor
DK1325115T3 (en) * 2000-06-26 2016-11-21 Zymogenetics Inc CYTOKINRECEPTOR ZCYTOR17
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
AU7309601A (en) 2000-06-28 2002-01-08 Genetics Inst Pd-l2 molecules: novel pd-1 ligands and uses therefor
RU2272644C2 (ru) * 2000-06-29 2006-03-27 Мерк Патент Гмбх Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина
US6902734B2 (en) 2000-08-07 2005-06-07 Centocor, Inc. Anti-IL-12 antibodies and compositions thereof
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
UA81743C2 (uk) 2000-08-07 2008-02-11 Центокор, Инк. МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
EP2177616B1 (de) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Lösliche Zcyctor 11 Cytokinrezeptoren
US20030215916A1 (en) * 2000-08-18 2003-11-20 Feder John N. Novel imidazoline receptor homologs
US20020119148A1 (en) * 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
ATE448306T1 (de) 2000-09-01 2009-11-15 Blood Res Center Veränderte, in gewünschter konformation stabilisierte polypeptide und verfahren zu deren herstellung
DE60138222D1 (de) * 2000-09-14 2009-05-14 Beth Israel Hospital Modulierung von il-2 und il-15 vermittelten t zellantworten
WO2002026781A2 (en) 2000-09-26 2002-04-04 Genentech, Inc. Ige receptor antagonists
EP1320606A2 (de) * 2000-09-29 2003-06-25 Bristol-Myers Squibb Company Identifikation und klonierung eines vollständigen humanen clnk-verwandeten genes, mist (mastzellen immunrezeptor signaltransducer)
US20030211549A1 (en) * 2000-10-06 2003-11-13 Murphy Andrew J. Functional proteins and therapeutic and diagnostic methods for use thereof
AU2002237733A1 (en) * 2000-11-07 2002-06-18 Board Of Regents, The University Of Texas System Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
US20030124142A1 (en) * 2000-12-04 2003-07-03 Fraser John David Immunomodulatory constructs and their uses
US20040253242A1 (en) * 2000-12-05 2004-12-16 Bowdish Katherine S. Rationally designed antibodies
US7396917B2 (en) 2000-12-05 2008-07-08 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
CA2436671C (en) 2000-12-05 2015-02-03 Alexion Pharmaceuticals, Inc. Rationally designed antibodies
US7056737B2 (en) * 2001-02-16 2006-06-06 Bristol-Myers Squibb Company Polynucleotides encoding a novel glycine receptor alpha subunit expressed in the gastrointestinal tract, HGRA4, and splice variant thereof
KR100900176B1 (ko) * 2001-03-07 2009-06-02 메르크 파텐트 게엠베하 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술
US8163289B2 (en) 2001-03-09 2012-04-24 Iterative Therapeutics, Inc. Methods and compositions involving polymeric immunoglobulin fusion proteins
EP1395605B8 (de) 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymere immunoglobulin-fusionsproteine, die auf fc-gamma-rezeptoren mit geringer affinität zielen
US6992174B2 (en) * 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2004533226A (ja) 2001-04-02 2004-11-04 ワイス Ｂ７−４に対するｐｄ−１、ａレセプター、およびその使用
US7507413B2 (en) 2001-04-12 2009-03-24 Human Genome Sciences, Inc. Albumin fusion proteins
US20050054051A1 (en) * 2001-04-12 2005-03-10 Human Genome Sciences, Inc. Albumin fusion proteins
US20060084794A1 (en) * 2001-04-12 2006-04-20 Human Genome Sciences, Inc. Albumin fusion proteins
US20050244931A1 (en) * 2001-04-12 2005-11-03 Human Genome Sciences, Inc. Albumin fusion proteins
ITRE20010042A1 (it) * 2001-04-24 2002-10-24 Corghi Spa Dispositivo sollevatore per macchine smontagomme
US20050089932A1 (en) * 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US7265208B2 (en) 2001-05-01 2007-09-04 The Regents Of The University Of California Fusion molecules and treatment of IgE-mediated allergic diseases
CA2446087C (en) * 2001-05-03 2013-06-18 Stephen D. Gillies Recombinant tumor specific antibody and use thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
JP4516719B2 (ja) 2001-05-11 2010-08-04 アムジエン・インコーポレーテツド Ｔａｌｌ−１と結合するペプチド及び関連分子
WO2002102320A2 (en) * 2001-06-15 2002-12-27 Tanox, Inc. Fce fusion proteins for treatment of allergy and asthma
US20060073141A1 (en) * 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
US7858095B2 (en) * 2001-07-24 2010-12-28 Astellas Us Llc Method for treating or preventing sclerotic disorders using CD-2 binding agents
EP1476180A4 (de) * 2001-08-13 2005-04-20 Univ Southern California Interleukin-2 mutanten mit verringerter toxizität
US6900292B2 (en) * 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
KR100942880B1 (ko) 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
JP2005508623A (ja) * 2001-08-30 2005-04-07 バイオレクシス ファーマシューティカル コーポレイション 改変されたトランスフェリン融合タンパク質
US6797493B2 (en) 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
WO2003030821A2 (en) * 2001-10-05 2003-04-17 Human Genome Sciences, Inc. Albumin fusion proteins
US7138370B2 (en) * 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
CA2463003A1 (en) * 2001-10-19 2003-04-24 Zymogenetics, Inc. Dimerized growth factor and materials and methods for producing it
AU2002363465A1 (en) * 2001-10-25 2003-05-19 The Government Of The United States Of America As Represented By The Secretary Of Health And Human S Efficient inhibition of hiv-1 viral entry through a novel fusion protein including of cd4
US20070118934A1 (en) * 2001-10-26 2007-05-24 Planet Biotechnology, Inc. Chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax
BR0214650A (pt) * 2001-12-04 2005-05-03 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
ATE451387T1 (de) * 2001-12-18 2009-12-15 Endocube Sas Neue mit dem zelltod assoziierte proteine aus der thap familie und par4 verwandte signalwege, die bei der kontrolle von apoptosis involviert sind
US7858297B2 (en) * 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2002364587A1 (en) * 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
ES2425738T3 (es) * 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
KR101271635B1 (ko) * 2001-12-21 2013-06-12 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
ATE401390T1 (de) 2002-01-18 2008-08-15 Zymogenetics Inc Zytokin (zcytor17-ligand)
DK1476181T3 (en) * 2002-01-18 2016-05-23 Biogen Ma Inc POLYALKYLENE POLYMER COMPOUNDS AND USE THEREOF
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
US20030211470A1 (en) * 2002-03-15 2003-11-13 Olson William C. CD4-IgG2-based salvage therapy of HIV-1 infection
EA200401342A1 (ru) * 2002-04-10 2005-08-25 Апплайд Резеч Системз Арс Холдинг Н. В. Новые антагонисты белков mcp
US20040016010A1 (en) * 2002-04-17 2004-01-22 Marion Kasaian IL-21 receptor knockout animal and methods of use thereof
EP1514927B1 (de) 2002-05-29 2010-05-19 Yamasa Corporation Verfahren zur produktion von nucleosid-diphosphat unter verwendung von polyphosphat: amp-phosphotransferase
EP1513554B9 (de) * 2002-05-30 2011-11-09 Macrogenics, Inc. Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
NZ519371A (en) * 2002-06-04 2004-11-26 Auckland Uniservices Ltd Immunomodulatory constructs and their uses
EP1369128A1 (de) * 2002-06-07 2003-12-10 Procorde GmbH Glycoprotein VI Inhibitoren und deren therapeutische Verwendung
US20070071744A1 (en) * 2002-06-07 2007-03-29 Gotz Munch Agents which bind to epitopes of glycoprotein VI
US20090130021A1 (en) * 2002-06-07 2009-05-21 Gotz Munch Methods, products and uses involving platelets and/or the vasculature
US7531178B2 (en) * 2002-06-07 2009-05-12 Trigen Gmbh Immunoadhesin comprising a glycoprotein VI domain
US8025873B2 (en) 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8029803B2 (en) 2002-06-20 2011-10-04 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US20070104710A1 (en) * 2002-06-28 2007-05-10 Domants Limited Ligand that has binding specificity for IL-4 and/or IL-13
AU2003280130B2 (en) 2002-06-28 2009-06-11 Centocor, Inc. Mammalian CH1 deleted mimetibodies, compositions, methods and uses
EP1517921B1 (de) * 2002-06-28 2006-06-07 Domantis Limited Dual-specifische liganden mit erhöhter halbwertszeit
CN1241946C (zh) * 2002-07-01 2006-02-15 美国福源集团 对多种细胞具刺激增生作用的人血清白蛋白重组融合蛋白
US20040115216A1 (en) * 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
KR20050037552A (ko) * 2002-07-15 2005-04-22 와이어쓰 Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물
US20040110681A1 (en) * 2002-08-08 2004-06-10 Xiao-Min Fan Method to identify targeting molecules
US20040136992A1 (en) 2002-08-28 2004-07-15 Burton Paul B. J. Compositions and method for treating cardiovascular disease
DE10251463A1 (de) * 2002-11-05 2004-05-19 BSH Bosch und Siemens Hausgeräte GmbH Elektrisch angetriebene Pumpe
US20050054054A1 (en) * 2002-11-12 2005-03-10 Foss Francine M. Interleukin-7 molecules with altered biological properties
JP4494977B2 (ja) * 2002-12-17 2010-06-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質
EP1578801A2 (de) * 2002-12-27 2005-09-28 Domantis Limited Dual-spezifischer einzeldomäne-antikörper welcher spezifisch ist für einen liganden und dessen rezeptor
US20110223168A1 (en) * 2002-12-27 2011-09-15 Greg Winter Ligand that has binding specificity for il-4 and/or il-13
GB0230203D0 (en) * 2002-12-27 2003-02-05 Domantis Ltd Fc fusion
EP2052713A3 (de) * 2003-01-13 2009-05-20 Macrogenics, Inc. Lösliche FcgammaR-Fusionsproteine und Verfahren zu deren Verwendung
EP1594530A4 (de) 2003-01-22 2006-10-11 Human Genome Sciences Inc Albuminfusionsproteine
CN1756767A (zh) * 2003-02-06 2006-04-05 诺和酶股份有限公司 在丝状真菌中表达人重链抗体
US20050096264A1 (en) * 2003-02-25 2005-05-05 Macdonald Lynn Methods for treating obesity and related conditions with glycoprotein hormone beta family hormones
MXPA05009743A (es) 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
US20050142139A1 (en) * 2003-03-21 2005-06-30 Norbert Schulke CD4-IgG2 formulations
AU2004223837C1 (en) * 2003-03-24 2012-03-15 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
AU2004224123A1 (en) * 2003-03-26 2004-10-07 Apogenix Gmbh Treatment of viral infections
AU2004238263A1 (en) * 2003-05-06 2004-11-25 Syntonix Pharmaceuticals, Inc. Inhibition of drug binding to serum albumin
PT1624891E (pt) † 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US8273347B2 (en) * 2003-05-13 2012-09-25 Depuy Spine, Inc. Autologous treatment of degenerated disc with cells
US7429378B2 (en) * 2003-05-13 2008-09-30 Depuy Spine, Inc. Transdiscal administration of high affinity anti-MMP inhibitors
DK1622939T3 (da) * 2003-05-13 2012-04-10 Merck Serono Sa Aktive varianter af det IL-18-bindende protein og medicinske anvendelser deraf
US7344716B2 (en) * 2003-05-13 2008-03-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of pro-inflammatory cytokines
KR20060014048A (ko) 2003-05-13 2006-02-14 디퍼이 스파인 인코포레이티드 퇴행성 디스크 질환을 치료하는 방법
US20040229878A1 (en) * 2003-05-13 2004-11-18 Depuy Spine, Inc. Transdiscal administration of specific inhibitors of P38 kinase
US7553827B2 (en) * 2003-08-13 2009-06-30 Depuy Spine, Inc. Transdiscal administration of cycline compounds
US7435808B2 (en) * 2003-06-25 2008-10-14 Bristol-Myers Squibb Company Polynucleotides encoding novel adiponectin receptor variant, AdipoR2v2
SI1639011T1 (sl) * 2003-06-30 2009-04-30 Domantis Ltd Pegilirana protitelesa z enojno domeno (dAb)
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
US8361467B2 (en) * 2003-07-30 2013-01-29 Depuy Spine, Inc. Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens
EP1660094A4 (de) 2003-08-26 2009-09-16 Univ Colorado Hemmer der serinprotease-aktivität und ihre verwendung bei verfahren und zusammensetzungen zur behandlung von bakterieninfektionen
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
UA89481C2 (uk) * 2003-09-30 2010-02-10 Центокор, Инк. Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування
WO2005035569A2 (en) * 2003-10-10 2005-04-21 Five Prime Therapeutics, Inc. Kiaa0779, splice variants thereof, and methods of their use
WO2005037999A2 (en) * 2003-10-14 2005-04-28 Biogen Idec Ma Inc. Treatment of cancer using antibodies to lrrc15
US8129506B2 (en) * 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
CA2545603A1 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. Neonatal fc receptor (fcrn)-binding polypeptide variants, dimeric fc binding proteins and methods related thereto
JP2007531513A (ja) 2003-11-13 2007-11-08 ハンミ ファーム．インダストリー カンパニー リミテッド 薬物のキャリアとして有用なＩｇＧＦｃ断片およびその製造方法
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
US8895540B2 (en) * 2003-11-26 2014-11-25 DePuy Synthes Products, LLC Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor
DK1699822T3 (da) * 2003-12-30 2008-08-04 Merck Patent Gmbh IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
ATE443724T1 (de) * 2004-01-22 2009-10-15 Merck Patent Gmbh Antikrebs-antikörper mit reduzierter komplementfixierung
MXPA06008918A (es) * 2004-02-06 2007-03-07 Astellas Llc Metodos de tratamiento de trastornos de la piel.
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
US20100028995A1 (en) * 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
KR20070004078A (ko) * 2004-03-31 2007-01-05 센토코 인코포레이티드 인간 ｇｌｐ-1 모방체, 조성물, 방법 및 용도
KR20070011558A (ko) * 2004-05-04 2007-01-24 제네상스 파머슈티컬스, 아이엔씨. 일배체형 마커 및 치료에 대한 반응을 측정하기 위해 이를이용하는 방법
CA2565259A1 (en) * 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
US20060063208A1 (en) * 2004-08-02 2006-03-23 Woolf Clifford J DRG11-responsive (DRAGON) gene and uses thereof
US7393662B2 (en) * 2004-09-03 2008-07-01 Centocor, Inc. Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
ATE470454T1 (de) * 2004-09-13 2010-06-15 Genzyme Corp Multimere konstrukte
CN101103045B (zh) 2004-09-24 2015-11-25 安姆根有限公司 修饰的Fc分子
RS52539B (sr) 2004-10-21 2013-04-30 Genentech Inc. Metod za tretiranje intraokularnih neovaskularnih bolesti
BRPI0516975A (pt) 2004-10-22 2008-09-30 Zymogenetics Inc anticorpo ou seu fragmento de ligação a antìgeno, composição farmacêutica, imunoconjugado, hibridoma, anticorpo monoclonal, e, uso de um anticorpo ou seu fragmento de ligação a antìgeno
US20090311259A1 (en) * 2004-11-17 2009-12-17 Victoria Smith Compositions and Methods for Treatment of Tumor of Hematopoietic Origin
ATE465176T1 (de) * 2004-12-09 2010-05-15 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
CN100515491C (zh) * 2005-01-04 2009-07-22 健能隆医药技术（上海）有限公司 白介素-22的医药用途
EP2311880A3 (de) 2005-01-05 2011-07-27 Biogen Idec MA Inc. Cripto-bindende Moleküle
WO2006081190A2 (en) 2005-01-25 2006-08-03 Five Prime Therapeutics, Inc. Compositions and methods for treating cardiac conditions
WO2006084327A1 (en) * 2005-02-09 2006-08-17 Apollo Life Sciences Limited A molecule and chimeric molecules thereof
KR100754667B1 (ko) 2005-04-08 2007-09-03 한미약품 주식회사 비펩타이드성 중합체로 개질된 면역글로불린 Ｆｃ 단편 및이를 포함하는 약제학적 조성물
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) * 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
EP3479844B1 (de) * 2005-04-15 2023-11-22 MacroGenics, Inc. Kovalente diabodies und verwendungen davon
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
KR101446989B1 (ko) 2005-05-06 2014-10-15 지모제넥틱스, 인코포레이티드 Ｉｌ-31 단클론성 항체 및 사용법
ES2402650T3 (es) * 2005-06-17 2013-05-07 Janssen Alzheimer Immunotherapy Métodos de purificación de anticuerpos anti A beta
PT2452694T (pt) 2005-06-30 2019-02-21 Janssen Biotech Inc Anticorpos anti-il-23, composições, métodos e utilizações
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
US7713521B2 (en) * 2005-08-12 2010-05-11 Schering Corporation MCP1 fusions
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
WO2007025991A2 (en) 2005-09-01 2007-03-08 Ares Trading S.A. Treatment of optic neuritis
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
TW200732346A (en) * 2005-10-13 2007-09-01 Virexx Medical Corp Chimeric hepatitis C virus antigens for eliciting an immune response
TW200722436A (en) * 2005-10-21 2007-06-16 Hoffmann La Roche A peptide-immunoglobulin-conjugate
BRPI0618488A2 (pt) * 2005-11-10 2011-08-30 Receptor Biologix Inc proteìnas de fusão de ìntron de fator de crescimento de hepatócito
JP5123197B2 (ja) 2005-11-14 2013-01-16 ライナット ニューロサイエンス コーポレイション カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
CN101454344A (zh) * 2005-12-01 2009-06-10 杜门蒂斯有限公司 与白细胞介素-1受体1型结合的非竞争性域抗体形式
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
AU2006330573A1 (en) * 2005-12-22 2007-07-05 Dhy & Co., Ltd Antibodies against interleukin-22 binding protein and its uses
EA035459B1 (ru) 2005-12-29 2020-06-19 Сентокор, Инк. Антитело против il-23p19
ES2384055T3 (es) * 2005-12-30 2012-06-28 Merck Patent Gmbh Variantes de la interleucina-12p40 con estabilidad mejorada
CA2635623C (en) 2005-12-30 2015-02-17 Michael Super Anti-cd19 antibodies with reduced immunogenicity
CA2636288C (en) 2006-01-10 2015-02-24 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
US7625564B2 (en) 2006-01-27 2009-12-01 Novagen Holding Corporation Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
TW200738752A (en) 2006-01-31 2007-10-16 Bayer Schering Pharma Ag Modulation of MDL-1 activity for treatment of inflammatory disease
GB0604187D0 (en) * 2006-03-02 2006-04-12 Fusion Antibodies Ltd Peptide and uses thereof
WO2007115150A2 (en) * 2006-03-31 2007-10-11 Centocor, Inc. Binding partners with immunoglobulin domains modified to have extended half-life
MX2008014971A (es) 2006-05-24 2008-12-05 Serono Lab Regimen de cladribine para tratar esclerosis multiple.
WO2007146959A2 (en) * 2006-06-12 2007-12-21 Receptor Biologix Inc. Pan-cell surface receptor- specific therapeutics
US20080305111A1 (en) * 2006-06-22 2008-12-11 Vaccinex, Inc. Anti-C35 antibodies for treating cancer
US20100021379A1 (en) * 2006-06-29 2010-01-28 The Regents Of The University Of California Chemical Antibodies for Immunotherapy and Imaging
CA2657581A1 (en) 2006-07-11 2008-01-17 Roy C. Levitt Rhinosinusitis prevention and therapy with proinflammatory cytokine inhibitors
US20080014285A1 (en) * 2006-07-13 2008-01-17 Di Mauro Thomas M Method of treating neurodegenerative brain disease with a composite comprising superparamagnetic nanoparticles and a therapeutic compound
CA2660519A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2067041A2 (de) 2006-10-03 2009-06-10 Biogen Idec MA, Inc. Biomarker und testreihen zur behandlung von krebs
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
PE20081250A1 (es) * 2006-11-28 2008-10-07 Centelion FUSIONES Fc CON RECEPTOR PARA FGF SOLUBLE MODIFICADAS, CON ACTIVIDAD BIOLOGICA MEJORADA
EP2099826B1 (de) 2007-01-05 2013-10-16 University Of Zurich Anti-beta-amyloid-antikörper und verwendung davon
ES2464815T3 (es) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
WO2008103471A2 (en) 2007-02-23 2008-08-28 The Trustees Of Columbia University In The City Of New York Methods to activate or block the hla-e/qa-1 restricted cd8+ t cell regulatory pathway to treat immunological disease
RU2479629C2 (ru) * 2007-03-07 2013-04-20 Гликофи, Инк. Продукция гликопротеинов с модифицированным фукозилированием
ES2642008T3 (es) 2007-05-11 2017-11-14 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
US7906149B2 (en) * 2007-05-25 2011-03-15 Boval Company, L.P. Method for treating allergic dermatitis
ES2456963T3 (es) * 2007-06-04 2014-04-24 Rappaport Family Institute For Research In The Medical Sciences Agentes para el tratamiento de enfermedades inflamatorias y métodos para usar los mismos
WO2008149147A2 (en) * 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
BRPI0814465B1 (pt) 2007-07-26 2021-11-23 Novagen Holding Corporation Proteína de fusão, dímero, método para produzir uma proteína de fusão, linhagem de célula, usos de uma proteína de fusão e de uma composição farmacêutica e composição farmacêutica
GB0717337D0 (en) * 2007-09-06 2007-10-17 Ucb Pharma Sa Method of treatment
CA2702217A1 (en) 2007-10-11 2009-04-16 Jayne Danska Modulation of sirp.alpha. - cd47 interaction for increasing human hematopoietic stem cell engraftment and compounds therefor
AU2008312580A1 (en) * 2007-10-16 2009-04-23 Symphogen A/S Compositions comprising optimized Her1 and Her3 multimers and methods of use thereof
CN101998965B (zh) * 2007-11-01 2014-03-12 安斯泰来制药有限公司 免疫抑制性多肽与核酸
WO2009061853A2 (en) * 2007-11-05 2009-05-14 Massachusetts Institute Of Technology Mutant interleukin-2 (il-2) polypeptides
CL2008003302A1 (es) 2007-11-09 2009-03-06 Genentech Inc Uso de una proteina de funsion kinasa 1 similar al receptor de activina (alk-1) y fc (alk1.fc) porque sirve para preparar un medicamento contra tumor,cancer o desordenes proliferativos.
ES2566963T3 (es) 2007-11-21 2016-04-18 Oregon Health & Science University Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
US20090312249A1 (en) * 2007-12-06 2009-12-17 Korea Advanced Institute Of Science And Technology TLR4 decoy receptor protein
LT2796466T (lt) 2007-12-07 2018-02-26 Zymogenetics, Inc. Humanizuotų antikūnų molekulės, specifinės il-31 atžvilgiu
US20090162351A1 (en) * 2007-12-21 2009-06-25 Depuy Spine, Inc. Transdiscal administration of inhibitors of p38 MAP kinase
US8986696B2 (en) * 2007-12-21 2015-03-24 Depuy Mitek, Inc. Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
US8669349B2 (en) 2008-04-02 2014-03-11 Macrogenics, Inc. BCR-complex-specific antibodies and methods of using same
CN102076713B (zh) * 2008-05-02 2015-03-25 诺华股份有限公司 改进的基于纤连蛋白的结合分子及其用途
SG190596A1 (en) 2008-05-06 2013-06-28 Genentech Inc Affinity matured crig variants
WO2010033279A2 (en) * 2008-06-04 2010-03-25 Macrogenics, Inc. Antibodies with altered binding to fcrn and methods of using same
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
EP2300501B1 (de) 2008-07-23 2014-08-20 Hanmi Science Co., Ltd. Polypeptidkomplex mit einem nicht-peptidyl-polymer mit drei funktionalen enden
US20100159485A1 (en) * 2008-12-19 2010-06-24 Centre For Dna Fingerprinting And Diagnostics Detection of mycobacterium tuberculosis
EP3521309A1 (de) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
JP2012521216A (ja) 2009-03-24 2012-09-13 テバ バイオファーマスーティカルズ ユーエスエー，インコーポレーテッド Ｌｉｇｈｔに対するヒト化抗体およびその使用
EP2413967A1 (de) 2009-04-01 2012-02-08 F. Hoffmann-La Roche AG Behandlung von insulinresistenten erkrankungen
AU2010233658B2 (en) 2009-04-10 2013-11-28 Ablynx Nv Improved amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of IL-6R related diseases and disorders
WO2010115995A2 (en) 2009-04-10 2010-10-14 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
MX2011011130A (es) 2009-04-22 2011-11-18 Alteogen Inc Proteina o peptido de fusion con vida media in vivo incrementada mantenido por liberacion in vivo sostenida, y metodo para incrementar la vida media in vivo usando el mismo.
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
EP3320920A1 (de) 2009-05-08 2018-05-16 Vaccinex, Inc. Anti-cd100-antikörper und verfahren zur verwendung davon
US10907209B2 (en) 2009-05-15 2021-02-02 University Health Network Compositions and methods for treating hematological cancers targeting the SIRPα CD47 interaction
EP2443137B1 (de) 2009-06-15 2015-05-20 Biokine Therapeutics Ltd. Neue chemokin-bindende peptide, die die fähigkeit, den fortschritt von autoimmunität, entzündung und krebs aufweisen
US20110039300A1 (en) 2009-08-10 2011-02-17 Robert Bayer Antibodies with enhanced adcc functions
WO2011019622A1 (en) 2009-08-14 2011-02-17 Genentech, Inc. Cell culture methods to make antibodies with enhanced adcc function
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
CN102666874B (zh) 2009-10-07 2016-06-01 宏观基因有限公司 由于岩藻糖基化程度的改变而表现出改善的效应子功能的含Fc区的多肽及其使用方法
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
US20110165122A1 (en) * 2009-11-10 2011-07-07 The Regents Of The University Of California Method for targeted and sustained antiviral therapy
EP2509997B1 (de) 2009-12-07 2017-08-30 i2 Pharmaceuticals, Inc. Konjugate mit einem antkörpersurrogatgerüst mit verbesserten pharmakokinetischen eigenschaften
US20130052195A1 (en) 2009-12-23 2013-02-28 Emergent Product Development Seattle,LLC Compositions Comprising TNF-alpha and IL-6 Antagonists and Methods of Use Thereof
US8637637B2 (en) 2010-01-12 2014-01-28 Bill Nai-Chau Sun Fc fusion proteins of human growth hormone
EA031209B9 (ru) 2010-01-15 2021-11-19 Кирин-Эмджен, Инк. Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
EP2536435B1 (de) 2010-02-18 2017-11-15 Janssen Biotech, Inc. Affenhomolog von menschlichem interferon omega
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
WO2011109280A1 (en) 2010-03-05 2011-09-09 Lerner Research Institute Methods and compositions to treat immune-mediated disorders
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
EP2552947A4 (de) 2010-03-26 2013-11-13 Dartmouth College Vista-regulatorisches t-zellen-mediator-protein, vista-bindende wirkstoffe und verwendung davon
US20110243943A1 (en) * 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
EP2558482B1 (de) 2010-04-16 2017-09-27 Janssen Biotech, Inc. Genetisch veränderte cysteinproteasen aus pflanzen und ihre verwendung
US8524217B2 (en) 2010-05-11 2013-09-03 Merck Sharp & Dohme Corp. MCP1-Ig fusion variants
US20130164380A1 (en) 2010-06-17 2013-06-27 Actogenix Nv Compositions and methods for treating inflammatory conditions
US9611310B2 (en) 2010-07-09 2017-04-04 Bioverativ Therapeutics Inc. Systems for factor VIII processing and methods thereof
CA2807127C (en) 2010-08-02 2019-02-12 Leslie S. Johnson Covalent diabodies and uses thereof
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
JP6097690B2 (ja) 2010-09-02 2017-03-15 ヴァクシネックス， インコーポレイテッド 抗ｃｘｃｌ１３抗体およびそれを用いる方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
EP3851459B1 (de) 2010-09-21 2024-05-01 Altor BioScience, LLC Multimere il-15-lösliche fusionsmoleküle sowie verfahren zu ihrer herstellung und verwendung
JP6126991B2 (ja) 2010-09-27 2017-05-10 ヤンセン バイオテツク，インコーポレーテツド ヒトｉｉ型コラーゲンに結合する抗体
US8940272B2 (en) 2010-10-11 2015-01-27 University Of Zurich Human anti-tau antibodies
US8883134B2 (en) * 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
EP3214442A1 (de) 2010-10-25 2017-09-06 F. Hoffmann-La Roche AG Behandlung von gastrointestinalen entzündungen und psoriasis und asthmaentzündung und psoriasis a
JP5933573B2 (ja) 2010-11-08 2016-06-15 ノバルティス アーゲー Ｃｘｃｒ２結合ポリペプチド
EP2651979B1 (de) 2010-12-17 2019-08-28 Neurimmune Holding AG Humane anti-sod-1 antikörper
EP3662932B1 (de) 2011-05-20 2021-04-07 H. Lundbeck A/S Anti-cgrp-zusammensetzungen und verwendung davon
NZ732970A (en) 2011-05-20 2022-08-26 H Lundbeck As Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
CN103957935B (zh) 2011-05-20 2018-04-03 奥尔德生物控股有限责任公司 抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
WO2012162068A2 (en) 2011-05-21 2012-11-29 Macrogenics, Inc. Deimmunized serum-binding domains and their use for extending serum half-life
TWI560200B (en) 2011-05-25 2016-12-01 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory and autoimmune disorders
MX357193B (es) 2011-06-23 2018-06-29 Univ Zuerich Moleculas de union anti-alfa sinucleina.
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20140039257A (ko) * 2011-07-08 2014-04-01 바이엘 인텔렉쳐 프로퍼티 게엠베하 릴랙신을 방출하는 융합 단백질 및 이의 용도
US9738707B2 (en) 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
US10138302B2 (en) * 2011-09-23 2018-11-27 Ablynx N.V. Methods for treating rheumatoid arthritis by administering interleukin-6 receptor antibodies
US20150017121A1 (en) * 2011-10-11 2015-01-15 Universitat Zurich Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
US11951157B2 (en) 2011-10-11 2024-04-09 Universitat Zurich Methods of treating malignant tumour with IL-12 and anti-PD-1 antibody
KR101828828B1 (ko) 2011-10-24 2018-03-29 할로자임, 아이엔씨 항-히알루로난 제제 치료를 위한 동반 진단 및 이의 사용 방법
AU2013202648B2 (en) 2012-01-10 2016-05-19 Konkuk University Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR102090969B1 (ko) 2012-03-02 2020-03-19 백시넥스 인코포레이티드 Ｂ 세포-매개 염증 질환의 치료 방법
WO2013172967A1 (en) 2012-05-17 2013-11-21 Extend Biosciences, Inc Carriers for improved drug delivery
US9695454B2 (en) 2012-05-23 2017-07-04 Glykos Finland Oy Production of fucosylated glycoproteins
TWI705073B (zh) 2012-06-22 2020-09-21 達特茅斯學院基金會 新穎之vista-ig構築體及vista-ig用於治療自體免疫、過敏及發炎病症之用途
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2878404A1 (en) 2012-07-10 2014-01-16 The Trustees Of The University Of Pennsylvania Biomaterials for enhanced implant-host integration
EP3613765B1 (de) 2012-08-03 2024-10-02 Dana-Farber Cancer Institute, Inc. Antikörper gegen das abstossende wegweisermolekül b (rgmb)
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
JP6368308B2 (ja) 2012-09-07 2018-08-01 トラスティーズ・オブ・ダートマス・カレッジ 癌の診断および治療のためのｖｉｓｔａ調節剤
WO2014062856A1 (en) 2012-10-16 2014-04-24 Halozyme, Inc. Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
US9969789B2 (en) 2012-12-17 2018-05-15 Trillium Therapeutics Inc. Treatment of CD47+ disease cells with SIRP alpha-Fc fusions
EP3653212B1 (de) 2012-12-20 2023-04-26 Purdue Research Foundation Chimären antigenrezeptor exprimierende t-zellen als antikrebsmittel
BR112015014751A8 (pt) 2012-12-21 2018-01-16 Biogen Int Neuroscience Gmbh anti-corpos anti-tau humanos e fragmento de ligação a tau dos mesmo, seu uso na preparação de um medicamento, bem como polipeptídeos codificando os mesmos.
WO2014102399A1 (en) 2012-12-31 2014-07-03 Neurimmune Holding Ag Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
AU2013205589A1 (en) 2013-03-08 2014-09-25 Vaccinex, Inc. Anti-CXCL13 antibodies and associated epitope sequences
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
EP2968520B1 (de) 2013-03-14 2021-05-12 MacroGenics, Inc. Mit einen aktivierungsrezeptor exprimierenden immuneffektorzellen immunreaktive bispezifische moleküle
EA037906B1 (ru) 2013-03-15 2021-06-04 Биовератив Терапьютикс Инк. Препараты полипептида фактора ix
ES2847383T3 (es) 2013-03-15 2021-08-03 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
EP2970422B1 (de) 2013-03-15 2018-04-18 F.Hoffmann-La Roche Ag Il-22-polypeptide und il-22-fc-fusionsproteine sowie verfahren zur verwendung
SMT202100008T1 (it) 2013-05-06 2021-03-15 Scholar Rock Inc Composizioni e metodi per la modulazione di fattore di crescita
EP3004877A4 (de) 2013-06-06 2017-04-19 Dana-Farber Cancer Institute, Inc. Zusammensetzungen und verfahren zur identifikation, beurteilung, vorbeugung und behandlung von krebs mit pd-l1-isoformen
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
AR096891A1 (es) 2013-07-12 2016-02-03 Hanmi Pharm Ind Co Ltd Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische Diabodies, die gpA33 und CD3 binden können und Anwendungen dieser
EP2839842A1 (de) 2013-08-23 2015-02-25 MacroGenics, Inc. Bispezifische monovalente Diabodies mit Fähigkeit zur Bindung von CD123 und CD3 und Verwendungen davon
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
EP3077048B1 (de) 2013-12-07 2019-07-17 Case Western Reserve University Zusammensetzungen und verfahren zur behandlung von thrombose
US11708411B2 (en) 2013-12-20 2023-07-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
RS63295B1 (sr) 2013-12-24 2022-06-30 Janssen Pharmaceutica Nv Anti-vista antitela i fragmenti
CA2935804A1 (en) 2014-01-14 2015-07-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using pd-l1 isoforms
EP3096776B1 (de) * 2014-01-22 2020-12-02 Antagonis Biotherapeutics GmbH Neuartige glycosaminoglycan-antagonisierende fusionsproteine und verfahren zur verwendung davon
US10556945B2 (en) 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HRP20240159T1 (hr) 2014-03-21 2024-04-12 Teva Pharmaceuticals International Gmbh Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
MY184189A (en) 2014-03-31 2021-03-24 Amgen K A Inc Methods of treating nail and scalp psoriasis
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
KR102762243B1 (ko) 2014-06-30 2025-02-05 알토 바이오사이언스 엘엘씨 Il-15-베이즈드 분자 및 이의 사용 방법
CN108064266A (zh) 2014-07-21 2018-05-22 格利科斯芬兰公司 在丝状真菌中具有哺乳动物样n-聚糖的糖蛋白的制备
EA201790165A1 (ru) 2014-07-29 2017-07-31 Нейриммьюн Холдинг Аг Происходящие от человека антитела к гентингтину (htt) и их применение
WO2016022597A1 (en) 2014-08-04 2016-02-11 Case Western Reserve University Targeting peptides and methods of use
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10717778B2 (en) 2014-09-29 2020-07-21 Duke University Bispecific molecules comprising an HIV-1 envelope targeting arm
AU2015326911C1 (en) 2014-09-30 2025-12-18 Neurimmune Holding Ag Human-derived anti-dipeptide repeats (DPRs) antibody
CA2963712A1 (en) 2014-10-21 2016-04-28 Ablynx Nv Treatment of il-6r related diseases
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
EP3226900A4 (de) 2014-12-05 2018-09-19 Immunext, Inc. Identifizierung von vsig8 als vermeintlicher vista-rezeptor und dessen verwendung zur herstellung von vista/vsig8-modulatoren
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
EP3250927B1 (de) 2015-01-28 2020-02-19 H. Hoffnabb-La Roche Ag Genexpressionsmarker und behandlung von multipler sklerose
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11820807B2 (en) 2015-06-12 2023-11-21 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
CN107922497B (zh) 2015-06-24 2022-04-12 詹森药业有限公司 抗vista抗体和片段
CN117964732A (zh) 2015-08-07 2024-05-03 Alx肿瘤生物技术公司 具有SIRP-α结构域或其变体的构建体
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
US11338065B2 (en) 2015-10-08 2022-05-24 Massachusetts Institute Of Technology In situ expansion of engineered devices for regeneration
EP3362074B1 (de) 2015-10-16 2023-08-09 President and Fellows of Harvard College Pd-1-modulation in regulatorischen t-zellen zur regulierung von t-zelleffektorimmunreaktionen
KR102828755B1 (ko) 2015-12-17 2025-07-03 바이오카인 테라퓨틱스 리미티드 케모카인 활성 및/또는 암세포 성장 억제용 저분자
WO2017103931A1 (en) 2015-12-17 2017-06-22 Biokine Therapeutics Ltd. Small molecules against cancer
CA3048613A1 (en) 2015-12-31 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Methods and uses for alpha-1 antitrypsin or recombinant forms thereof, on steroid-refractory graft versus host disease involving gastrointestinal complications
CN109069626A (zh) 2016-02-12 2018-12-21 詹森药业有限公司 抗-vista(b7h5)抗体
US11072652B2 (en) 2016-03-10 2021-07-27 Viela Bio, Inc. ILT7 binding molecules and methods of using the same
EP3439675A4 (de) 2016-04-08 2019-12-18 Purdue Research Foundation Verfahren und zusammensetzungen für car-t-zelltherapie
TWI781098B (zh) 2016-04-15 2022-10-21 美商宏觀基因股份有限公司 新穎的ｂ７-ｈ３-結合分子、其抗體藥物綴合物及其使用方法
US11649283B2 (en) 2016-04-15 2023-05-16 Immunext, Inc. Anti-human vista antibodies and use thereof
KR102463844B1 (ko) 2016-05-27 2022-11-08 알토 바이오사이언스 코포레이션 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
JP2018035137A (ja) 2016-07-13 2018-03-08 マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
KR20220031944A (ko) 2016-09-23 2022-03-14 테바 파마슈티컬스 인터내셔널 게엠베하 불응성 편두통의 치료
EP3529263B1 (de) 2016-10-21 2025-08-06 Altor BioScience Corporation Multimere auf il-15-basierende moleküle
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
EP3573658A4 (de) 2017-01-30 2021-07-21 Janssen Biotech, Inc. Anti-tnf-antikörper, zusammensetzungen und verfahren zur behandlung von aktiver psoriatischer arthritis
US11649288B2 (en) 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
KR20190115042A (ko) 2017-02-07 2019-10-10 얀센 바이오테크 인코포레이티드 활성 강직성 척추염의 치료를 위한 항-tnf 항체, 조성물, 및 방법
WO2018160540A1 (en) 2017-02-28 2018-09-07 Sanofi Therapeutic rna
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
KR20250150164A (ko) 2017-03-06 2025-10-17 알토 바이오사이언스 엘엘씨 Il-12 및 il-18로의 il-15-기반 융합
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies
ES2994451T3 (en) 2017-04-20 2025-01-24 Atyr Pharma Inc Compositions for treating lung inflammation
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
EP3676289B1 (de) 2017-08-28 2026-03-04 Altor BioScience, LLC Il-15-basierte fusionen zu il-7 und il-21
CN111356460A (zh) 2017-11-24 2020-06-30 默克专利股份公司 用于治疗进展型形式的多发性硬化症的克拉屈滨疗法
AU2019209428B2 (en) 2018-01-22 2025-06-26 Endocyte, Inc. Methods of use for CAR T cells
EP3743088B1 (de) 2018-01-26 2022-10-12 F. Hoffmann-La Roche AG Il-22 fc zusammensetzungen und verfahren zu ihrer verwendung
JP7349995B2 (ja) 2018-01-26 2023-09-25 ジェネンテック， インコーポレイテッド ＩＬ－２２ Ｆｃ融合タンパク質及び使用方法
CA3090089A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
KR20200123118A (ko) 2018-02-21 2020-10-28 제넨테크, 인크. IL-22 Fc 융합 단백질로 치료를 위한 투약
TW202000229A (zh) 2018-02-23 2020-01-01 美商安德賽特公司 Car t細胞療法之順序方法
EP3759125A4 (de) 2018-02-28 2021-12-08 Dana-Farber Cancer Institute, Inc. Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien
US11168138B2 (en) 2018-03-26 2021-11-09 Altor Bioscience, Llc Anti-PDL1, IL-15 and TGF-beta receptor combination molecules
EP3773658A4 (de) 2018-04-06 2022-04-27 Dana-Farber Cancer Institute, Inc. Kir3dl3 als hla2-rezeptor, anti-hhla2-antikörper und ihre verwendungen
CN110396133B (zh) 2018-04-25 2021-07-23 免疫靶向有限公司 一种以白介素12为活性成分的融合蛋白型药物前体
WO2019209078A1 (ko) 2018-04-26 2019-10-31 주식회사 굳티셀 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
CN112638406B (zh) 2018-06-22 2025-04-22 科优基因公司 白介素-2变体及其使用方法
EP3815706A4 (de) * 2018-06-28 2022-03-16 National University Corporation Okayama University Mittel zur verbesserung der phagozytosefähigkeit von neutrophilen
AU2019309472A1 (en) * 2018-07-24 2021-03-18 Good T Cells, Inc. Composition for preventing or treating immune-related diseases
CA3106563A1 (en) 2018-07-26 2020-01-30 Atyr Pharma, Inc. Compositions and methods for treating nrp2-associated diseases
CN110964116A (zh) 2018-09-26 2020-04-07 北京辅仁瑞辉生物医药研究院有限公司 GLP1-Fc融合蛋白及其缀合物
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
US11639380B2 (en) 2019-01-08 2023-05-02 H. Lundbeck A/S Acute treatment and rapid treatment of headache using anti-CGRP antibodies
KR20210116540A (ko) 2019-01-15 2021-09-27 얀센 바이오테크 인코포레이티드 소아 특발성 관절염의 치료를 위한 항-tnf 항체 조성물 및 방법
EP3914618A1 (de) 2019-01-23 2021-12-01 Janssen Biotech, Inc. Anti-tnf-antikörper-zusammensetzungen zur verwendung in verfahren zur behandlung von psoriatischer arthritis
KR20210126078A (ko) 2019-02-13 2021-10-19 더 브리검 앤드 우먼즈 하스피털, 인크. 항-말초 림프절 어드레신 항체 및 그의 용도
WO2020183271A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
CA3133383A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Methods for producing anti-tnf antibody compositions
WO2020183269A1 (en) 2019-03-14 2020-09-17 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
CA3090315C (en) 2019-05-15 2023-09-19 Biokine Therapeutics Ltd. 8-phenoxy-quinolinone derivatives for treating cancer, inhibiting chemokine activity and/or inducing cell death
TWI905099B (zh) 2019-05-21 2025-11-21 瑞士商諾華公司 Cd19 結合分子及其用途
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
MX2021014882A (es) 2019-06-03 2022-03-25 Janssen Biotech Inc Anticuerpos anti-tnf, composiciones y métodos para el tratamiento de la espondilitis anquilosante activa.
MA56015A (fr) 2019-06-03 2022-04-06 Janssen Biotech Inc Compositions d'anticorps anti-tnf et méthodes pour le traitement de l'arthrite psoriasique
WO2021028752A1 (en) 2019-08-15 2021-02-18 Janssen Biotech, Inc. Anti-tfn antibodies for treating type i diabetes
BR112022008817A2 (pt) 2019-11-27 2022-07-26 Alx Oncology Inc Terapias combinadas para tratamento de câncer
JP7807076B2 (ja) 2019-12-13 2026-01-27 キュージーン インコーポレイテッド 新規インターロイキン－１５（ｉｌ－１５）融合タンパク質およびその使用
WO2021150925A1 (en) 2020-01-24 2021-07-29 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
EP4100428A4 (de) 2020-02-04 2024-03-06 Seattle Children's Hospital (DBA Seattle Children's Research Institute) Chimäre anti-dinitrophenol-antigenrezeptoren
EP4545566A3 (de) 2020-02-28 2025-10-08 The Brigham and Women's Hospital Inc. Selektive modulation der signalisierung der transformierenden wachstumsfaktor-beta-superfamilie über multispezifische antikörper
US11725043B2 (en) 2020-03-05 2023-08-15 DiaMedica USA Inc. Ulinastatin polypeptides
CA3077973A1 (en) 2020-04-06 2021-10-06 H. Lundbeck A/S Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
US20230227511A1 (en) * 2020-05-14 2023-07-20 Nippon Medical School Foundation Therapeutic or preventive agent for infectious disease
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
CA3194812A1 (en) 2020-09-10 2022-03-17 Merck Patent Gmbh Novel treatment regimen for the treatment of autoimmune disorders
JP2024520902A (ja) 2021-05-13 2024-05-27 エーエルエックス オンコロジー インコーポレイテッド がんを治療するための併用療法
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023281462A1 (en) 2021-07-09 2023-01-12 Janssen Biotech, Inc. Manufacturing methods for producing anti-tnf antibody compositions
CN117957251A (zh) 2021-07-09 2024-04-30 詹森生物科技公司 用于制备抗tnf抗体组合物的制造方法
EP4440594A2 (de) 2021-11-29 2024-10-09 Dana-Farber Cancer Institute, Inc. Verfahren und zusammensetzungen zur modulierung von riok2
WO2023168426A1 (en) 2022-03-03 2023-09-07 Enosi Therapeutics Corporation Compositions and cells containing mixtures of oligo-trap fusion proteins (ofps) and uses thereof
US20250197448A1 (en) 2022-03-11 2025-06-19 University Of Rochester Cyclopeptibodies and uses thereof
WO2023213779A1 (en) 2022-05-02 2023-11-09 Novo Nordisk A/S Novel anti-angptl3 antibodies suitable for high concentration compositions and subcutaneous administration
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
WO2024186690A2 (en) 2023-03-03 2024-09-12 Enosi Therapeutics Corporation Oligo-trap fusion proteins (ofps) and uses thereof
EP4709406A2 (de) 2023-05-11 2026-03-18 University Hospitals Cleveland Medical Center Anxiolytische therapie

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
DE2247163A1 (de) 1972-09-26 1974-03-28 Merck Patent Gmbh Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
CA1023287A (en) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Process for the preparation of carrier-bound proteins
GB1479268A (en) 1973-07-05 1977-07-13 Beecham Group Ltd Pharmaceutical compositions
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4002531A (en) 1976-01-22 1977-01-11 Pierce Chemical Company Modifying enzymes with polyethylene glycol and product produced thereby
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (en) 1977-02-17 1981-01-20 Hideo Hirohara Enzyme immobilization with pullulan gel
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
JPS5811808A (ja) 1981-07-16 1983-01-22 Niles Parts Co Ltd 方位検出表示回路
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4444878A (en) 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
JPS59125144A (ja) 1982-12-30 1984-07-19 ソニー株式会社 デイジタル信号伝送方法
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3486314D1 (de) 1983-04-20 1994-07-07 Youri Agabekov Zusammenbau einer Stecklampenfassung und einer Lichtleiste.
US4630115A (en) 1983-05-09 1986-12-16 The General Electric Company, P.L.C. Cathode ray tube display device
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
EP0173494A3 (de) * 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimäre Rezeptoren durch Verbindung und Expression von DNS
US4745055A (en) 1985-05-07 1988-05-17 California Biotechnology Inc. Fused protein for enzyme immunoassay system
DE3523701A1 (de) * 1985-07-03 1987-01-08 Bayer Ag Verfahren zur herstellung von proteinen und polypeptiden
DE3712985A1 (de) * 1987-04-16 1988-11-03 Hoechst Ag Bifunktionelle proteine
DE3751908T2 (de) 1986-07-07 1997-02-06 Centocor Inc Chimärisches Murine-Mensch-Immunoglobulin, spezifisch für tumorassoziertes 17-1A Antigen
NO873164L (no) 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
GB8623843D0 (en) 1986-10-03 1987-10-21 Airtech Ltd Detection of unsafe voltages on mobile equipment
GB8626412D0 (en) 1986-11-05 1986-12-03 Clark M R Antibodies
CA1339546C (en) * 1986-11-12 1997-11-18 Thomas Quertermours Recombinant hybrid immunogloblin molecules an method of use
CA1339445C (en) 1986-11-12 1997-09-09 The General Hospital Corporation Recombinant hybrid immunoglobulin molecules and method of use
ES2073394T3 (es) * 1987-06-10 1995-08-16 Dana Farber Cancer Inst Inc Constructos de anticuerpos bifuncionales y su utilizacion para destruir selectivamente las poblaciones celulares.
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
SE459586B (sv) * 1987-09-14 1989-07-17 Mta Szegedi Biolog Koezponti Strukturgen som kodar foer autentiskt humant serum albumin och foerfarande foer dess framstaellning
ES2058199T3 (es) * 1987-09-23 1994-11-01 Bristol Myers Squibb Co Heteroconjugados de anticuerpos para la eliminacion de celulas infectadas por el vih.
PT88641B (pt) * 1987-10-02 1993-04-30 Genentech Inc Metodo para a preparacao de uma variante de adesao
GB8725529D0 (en) * 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US4978745A (en) * 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
ZA89430B (en) * 1988-01-22 1989-10-25 Gen Hospital Corp Cloned genes encoding ig-cd4 fusion proteins and the use thereof
EP0325224B1 (de) * 1988-01-22 1996-07-31 ZymoGenetics, Inc. Verfahren zur Herstellung von sekretierten Rezeptoranalogen
GB8801756D0 (en) 1988-01-27 1988-02-24 Shell Int Research Copolymer composition
SE8802176D0 (sv) * 1988-06-10 1988-06-10 Kabigen Ab Fusion protein and its use
FI903489A0 (fi) * 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
EP1201757A3 (de) 1988-12-22 2002-09-11 Genentech, Inc. Verfahren zur Herstellung von wasserlöslichen Polypeptiden
CA2010321C (en) * 1989-02-21 2004-04-06 Thomas F. Tedder Lymphocyte-associated cell surface protein
DK0745852T3 (da) * 1989-03-16 2002-10-14 Blood Res Center Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
EP0394827A1 (de) * 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimärische CD4-Immunoglobulin-Polypeptide
ATE92107T1 (de) * 1989-04-29 1993-08-15 Delta Biotechnology Ltd N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
IE901736L (en) * 1989-05-17 1990-11-17 Fuller H B Licensing Financ Polypeptide-antibody conjugate for inhibiting cell adhesion
ES2096590T3 (es) * 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
FR2650598B1 (fr) * 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
WO1991002743A1 (en) * 1989-08-23 1991-03-07 The General Hospital Corporation Non-human primate cd4 polypeptides, fusions thereof, dna encoding, and uses thereof
ATE152174T1 (de) * 1989-09-20 1997-05-15 Abbott Lab Verfahren zur herstellung von fusionsproteinen

Also Published As

Publication number Publication date
DE69033705D1 (de) 2001-03-29
JPH05503009A (ja) 1993-05-27
DE122008000063I2 (de) 2011-06-16
DE122008000063I1 (de) 2009-02-19
DE69033705T2 (de) 2001-08-02
EP1029870A2 (de) 2000-08-23
HK1013298A1 (en) 1999-08-20
ES2155819T3 (es) 2001-06-01
NL300372I1 (nl) 2009-02-02
EP1970386A2 (de) 2008-09-17
CA2072642A1 (en) 1991-05-23
WO1991008298A2 (en) 1991-06-13
DE69033705T3 (de) 2007-07-12
DK0526452T3 (da) 2001-06-18
EP0526452B1 (de) 2001-02-21
ES2308826T3 (es) 2008-12-01
CA2072642C (en) 2002-07-23
EP0526452B2 (de) 2007-01-03
DE69034253D1 (de) 2008-07-10
EP0526452A1 (de) 1993-02-10
EP1029870B1 (de) 2008-05-28
US5116964A (en) 1992-05-26
ATE396735T1 (de) 2008-06-15
DK1029870T3 (da) 2008-09-29
ES2155819T5 (es) 2007-09-16
WO1991008298A3 (en) 1991-10-17
DK0526452T4 (da) 2007-05-07
HK1030222A1 (en) 2001-04-27
EP1029870A3 (de) 2000-12-13
JP2002325589A (ja) 2002-11-12
LU91498I2 (fr) 2009-01-19
GR3035856T3 (en) 2001-08-31
EP1970386A8 (de) 2009-07-08

Similar Documents

Publication Publication Date Title
ATE199261T1 (de) Hybride immunglobuline
EP0315683A4 (de) Dns sequenzen, rekombinante dns-moleküle sowie verfahren zur herstellung des an der lymphocyten-funktion assoziierten antigens-3.
ATE112802T1 (de) Herstellung von funktionellen menschlichen urokinasepolypeptiden.
DE3585953D1 (de) Dna-fragmente, expressionsvektoren, proteine, wirte und verfahren zur herstellung der proteine.
ATE167518T1 (de) Zellzyklusprotein in säugetieren
ATE387458T1 (de) Fas-antigenbindender ligand
DK0666914T3 (da) Hidtil ukendt P-selectin-ligandprotein
DE69132902D1 (de) Methoden zur identifizierung heterofunktionaler fusionsproteine
ES545725A0 (es) Procedimiento para preparar peptidos de interferon
FI863626A7 (fi) DNA-sekvenssejä, yhdistelmä-DNA -molekyylejä ja menetelmiä ihmisen lip okortiinin kaltaisia polypeptidejä.
ATE102994T1 (de) Verfahren zur herstellung von proteinen.
NO169819C (no) Fremgangsmaate for fremstilling av hybrid polypeptid og dna-molekyl for bruk i denne
ES2023669B3 (es) Procedimiento y dispositivo de moldeo en forma de bloques carbonados por compactacion multiaxial.
EP0676413A3 (de) Interferon alpha/beta bindendes Protein, seine Herstellung und Anwendung.
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
UEP Publication of translation of european patent specification

Ref document number: 0526452

Country of ref document: EP

EELA Cancelled due to lapse of time